…
Echo IQ Limited, an artificial intelligence (AI) and medical technology company, engages in the development and application of AI for the cardiac diagnostics sector in Australia. It offers EchoSolv, a machine-learning and AI-based clinical decision support software for use as an adjunct to echocardiography in the assessment of severe aortic stenosis and other cardiovascular conditions. The company has a research collaboration with Mayo Clinic to assess cardiac risk in patients receiving cancer therapy. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is headquartered in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Echoiq Ltd is an Australian-listed company (ASX: EIQ) for which publicly available materials provide limited detail on core operations and product lines. Because public disclosures are sparse, major long-term growth drivers are not clearly described; investors may find the company potentially interesting if future filings demonstrate a clear revenue model, scalable customer traction and disciplined capital allocation.
The primary investment risks are the lack of transparency and limited public information, which increase execution, liquidity and valuation uncertainty and make ongoing regulatory filings and management disclosures critical for assessment.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -18.57M | -13.26M | -5.41M | -8.27M | -6.49M |
| Net income | -18.57M | -13.26M | -5.41M | -8.27M | -5.99M |
| Selling general administrative | 13.70M | 9.59M | 4.23M | 4.38M | 4.24M |
| Selling and marketing expenses | - | 0.27M | 0.01M | 0.11M | -0.90M |
| Gross profit | -16.31M | -3.14M | -2.88M | -7.01M | -3.19M |
| Reconciled depreciation | 0.55M | - | 0.60M | 0.61M | 0.64M |
| Ebit | -19.85M | -13.13M | -5.41M | -8.27M | -6.53M |
| Ebitda | -19.30M | -12.74M | -4.81M | -7.66M | -5.89M |
| Depreciation and amortization | 0.55M | 0.39M | 0.60M | 0.61M | 0.64M |
| Operating income | -19.85M | -13.00M | -5.92M | -8.27M | -6.53M |
| Other operating expenses | 19.94M | 13.10M | 5.97M | 8.37M | 6.78M |
| Interest expense | - | - | - | - | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.52M | 0.20M | - | - | 0.00M |
| Net interest income | 0.52M | - | - | - | - |
| Extraordinary items | - | - | 0.00M | 0.41M | 0.50M |
| Income tax expense | - | - | 0.00M | 0.00M | -0.50M |
| Total revenue | 0.09M | 0.10M | 0.04M | 0.11M | 0.25M |
| Total operating expenses | 3.54M | 9.86M | 3.04M | 1.26M | 3.34M |
| Cost of revenue | 16.40M | 3.24M | 2.92M | 7.12M | 3.44M |
| Total other income expense net | 1.28M | -0.27M | 0.51M | -0.00M | 0.04M |
| Discontinued operations | - | - | - | 0.41M | 0.50M |
| Net income from continuing ops | -18.57M | - | -5.41M | -8.21M | -6.49M |
| Net income applicable to common shares | - | -13.26M | -5.41M | -7.86M | -6.17M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 13.88M | 23.37M | 8.26M | 10.38M | 9.97M |
| Intangible assets | 4.16M | 4.69M | - | 6.37M | 7.16M |
| Other current assets | 0.78M | 11.81M | 0.24M | 0.00M | 0.50M |
| Total liab | 2.25M | 0.62M | 1.49M | 2.95M | 2.13M |
| Total stockholder equity | 11.63M | 22.76M | 6.77M | 7.44M | 7.84M |
| Other current liab | 1.47M | 0.39M | 0.12M | 0.01M | 0.55M |
| Common stock | 68.15M | 64.62M | 41.53M | 36.00M | 30.40M |
| Capital stock | 68.15M | - | - | 36.00M | 30.40M |
| Retained earnings | -65.52M | -49.03M | -39.10M | -35.14M | -27.90M |
| Good will | - | - | - | - | 0.14M |
| Other assets | - | - | - | - | 0.00M |
| Cash | 8.71M | 6.62M | 2.12M | 3.28M | 2.41M |
| Cash and equivalents | - | - | - | - | 2.41M |
| Total current liabilities | 2.25M | 0.62M | 1.49M | 2.95M | 2.13M |
| Current deferred revenue | 0.01M | - | 0.01M | 0.01M | 0.01M |
| Net debt | -8.71M | -6.62M | -2.12M | -3.28M | -2.41M |
| Short term debt | - | - | - | 0.08M | 0.04M |
| Other stockholder equity | - | - | - | -0.81M | -2.69M |
| Property plant equipment | - | - | - | 0.03M | 0.04M |
| Total current assets | 9.64M | 18.65M | 2.45M | 3.98M | 2.76M |
| Long term investments | 0.01M | - | - | 0.00M | 0.00M |
| Net tangible assets | - | - | - | 1.02M | 1.05M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | 0.15M | 0.21M | 0.10M | 0.64M | 0.36M |
| Accounts payable | 0.76M | 0.22M | 1.36M | 2.85M | 1.53M |
| Accumulated other comprehensive income | 9.00M | 7.17M | 4.33M | 6.58M | 5.33M |
| Non currrent assets other | - | - | 5.78M | 0.00M | 0.00M |
| Non current assets total | 4.23M | 4.73M | 5.80M | 6.41M | 7.21M |
| Long term debt total | - | - | - | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | 0.00M | -0.06M | -0.37M |
| Change to liabilities | - | - | - | 0.05M | 0.29M |
| Total cashflows from investing activities | 11.46M | -11.55M | - | -0.06M | 0.14M |
| Total cash from financing activities | 1.22M | 22.56M | 2.77M | 5.88M | 1.55M |
| Change to operating activities | - | - | - | 0.04M | -0.15M |
| Net income | -18.57M | -13.26M | -5.41M | -8.27M | -6.49M |
| Change in cash | 2.09M | 4.50M | -1.16M | 0.87M | -1.41M |
| Begin period cash flow | 6.62M | 2.12M | 3.28M | 2.41M | 3.81M |
| End period cash flow | 8.71M | 6.62M | 2.12M | 3.28M | 2.41M |
| Total cash from operating activities | -10.56M | -6.51M | -3.92M | -4.94M | -2.58M |
| Issuance of capital stock | 1.22M | - | 2.76M | 6.07M | 1.55M |
| Depreciation | 0.55M | 0.58M | 0.60M | 0.61M | 0.64M |
| Other cashflows from investing activities | 11.52M | -11.52M | 0.00M | - | 0.50M |
| Change to inventory | - | - | - | -0.09M | -0.14M |
| Change to account receivables | 0.07M | -0.11M | -0.11M | 0.12M | -0.16M |
| Sale purchase of stock | - | - | - | -0.19M | -0.17M |
| Other cashflows from financing activities | - | - | 2.76M | 0.19M | 0.17M |
| Change to netincome | - | - | - | 2.50M | 2.63M |
| Capital expenditures | 0.05M | 0.04M | 0.00M | 0.34M | 0.37M |
| Change in working capital | 1.21M | -0.16M | -0.08M | 0.20M | -0.02M |
| Stock based compensation | - | 6.72M | 0.81M | 2.38M | 2.63M |
| Other non cash items | 6.25M | -0.39M | 0.15M | 3.56M | 4.44M |
| Free cash flow | -10.62M | -6.54M | -3.92M | -5.28M | -2.95M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EIQ Echoiq Ltd |
-0.05 8.47% |
0.54 | - | - | 5395.50 | 40.77 | 5059.22 | -8.27 |
| PME Pro Medicus Ltd |
1.15 0.71% |
162.15 | 64.69 | 89.29 | 65.34 | 37.37 | 63.47 | 81.35 |
| AYA ARTRYA Ltd |
-0.24 6.30% |
3.57 | - | - | 23230.33 | 8.10 | 20004.93 | 0.33 |
| CGS Cogstate Ltd |
-0.06 1.78% |
3.31 | 36.00 | 28.17 | 9.16 | 6.93 | 6.33 | 19.23 |
| ALC Alcidion Group Ltd |
- -% |
0.10 | - | 1.23 | 2.68 | 1.49 | 2.75 | 18.06 |
Echo IQ Limited, an artificial intelligence (AI) and medical technology company, engages in the development and application of AI for the cardiac diagnostics sector in Australia. It offers EchoSolv, a machine-learning and AI-based clinical decision support software for use as an adjunct to echocardiography in the assessment of severe aortic stenosis and other cardiovascular conditions. The company has a research collaboration with Mayo Clinic to assess cardiac risk in patients receiving cancer therapy. The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021. Echo IQ Limited is headquartered in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew Grover | Interim MD & Exec. Chairman | NA |
| Jacki McAvenna | Chief Financial Officer | NA |
| Mr. Philip Woolff | Chief Operating Officer | NA |
| Sean Bryceland | Chief Technology Officer | NA |
| Prof. David Playford | Chief Medical Officer- Medical Advisory Team | NA |
| Mr. Donald L. Fowler | Pres of Echo IQ USA | NA |
| Ms. Jessamyn Sarah Lyons AGIA, B.Com. | Joint Company Secreatry | NA |
| Adam Uren | Joint Company Sec. | NA |
| Mr. Andrew Grover | Interim MD & Executive Chairman | NA |
| Mr. Donald L. Fowler | President of Echo IQ USA | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.